Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Apr;77(4):1299-1306.
doi: 10.1111/all.15205. Epub 2022 Jan 12.

Comparing biologicals for severe chronic rhinosinusitis with nasal polyps: A network meta-analysis

Affiliations
Comment

Comparing biologicals for severe chronic rhinosinusitis with nasal polyps: A network meta-analysis

José Laerte Boechat et al. Allergy. 2022 Apr.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Agache I, Song Y, Alonso-Coello P, et al. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines. Allergy. 2021;76:2337-2353.
    1. Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021. doi:10.1016/S2213-2600(21)00097-7
    1. Tversky J, Lane AP, Azar A. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial. Clin Exp Allergy. 2021;51:836-844.
    1. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2021. doi:10.1016/j.jaci.2021.08.030
    1. Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74:2312-2319. doi:10.1111/all.13875

Substances

LinkOut - more resources